Comparative Pharmacology
Head-to-head clinical analysis: DEFLAZACORT versus PREDNISOLONE TEBUTATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEFLAZACORT versus PREDNISOLONE TEBUTATE.
DEFLAZACORT vs PREDNISOLONE TEBUTATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Deflazacort is a glucocorticoid prodrug that is metabolized to its active form, 21-desacetyldeflazacort. It binds to glucocorticoid receptors, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and modulating cytokine production.
Corticosteroid that binds to glucocorticoid receptors, leading to modulation of gene expression and suppression of inflammatory mediators (e.g., prostaglandins, leukotrienes) and immune cell activity.
6-90 mg orally once daily; initial dose typically 6-30 mg/day, maintenance as lowest effective dose; taper gradually upon discontinuation.
20-60 mg intramuscularly or intra-articularly once daily as a single dose or divided every 6-12 hours; dose varies by indication and severity.
None Documented
None Documented
Clinical Note
moderateDeflazacort + Gatifloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Gatifloxacin."
Clinical Note
moderateDeflazacort + Rosoxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Rosoxacin."
Clinical Note
moderateDeflazacort + Levofloxacin
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Levofloxacin."
Clinical Note
moderateDeflazacort + Trovafloxacin
Terminal half-life of the active metabolite Δ6-deflazacort is 1.1–1.9 hours; parent drug half-life is approximately 1–2 hours. Clinical glucocorticoid effect persists for 12–24 hours due to receptor binding.
Terminal half-life: 2-4 hours (plasma); clinical effects persist longer (18-36 hours) due to prolonged receptor occupancy and transcriptional effects.
Renal (approximately 70% as metabolites, <5% unchanged); biliary/fecal (approximately 30%)
Renal: primarily as metabolites, <20% unchanged; small fecal/biliary contribution.
Category C
Category D/X
Corticosteroid
Corticosteroid
"The risk or severity of adverse effects can be increased when Deflazacort is combined with Trovafloxacin."